Ridaforolimus and Vorinostat in Treating Patients With Advanced Solid Tumors or Lymphoma

Inclusion Criteria

• Histological or cytological confirmation of a solid, malignant tumor or lymphoma that is refractory to standard therapies or for which no standard therapies exist
• Patients must have received at least one prior systemic therapy
• Measureable disease by RECIST v 1.1
• ECOG PS 0 or 1
• ANC >= 1500/uL
• Hgb >= 9 g/dL
• Platelets >= 100,000/uL
• AST/SGOT and ALT/SGPT = = 50 ml/min
• Female patients of childbearing potential must have a negative serum or urine pregnancy test = = 3 weeks earlier; for patients receiving targeted therapy, treatment must be discontinued at least five half-lives prior to initiation of day 1 of study treatment
• Patients who have taken valproic acid = = 350 mg/dL or serum triglycerides >= 400 mg/d
• Poorly controlled Type 1 or 2 diabetes, defined as hemoglobin A1C greater than 8% or a fasting glucose of > 160 mg/dL
• Active infection requiring antibiotics
• Anaphylactic reaction to macrolide antibiotics, Tween 80 (polysorbate 80)
• Patients who are not adequately recovered from a prior surgical procedure or major surgical procedure within 2 weeks prior to the first dose of study drug
• Myocardial infarction of unstable angina within 3 months of study entry
• NY Heart Association class III or IV congestive heart failure
• Known active parenchymal brain metastases; patients who have had brain metastases resected, or have received radiation therapy ending > 4 weeks prior to study entry are eligible if they meet all of the following criteria: 1) residual neurologic symptoms = 3 years is allowed